Veliflapon
Veliflapon (BAY X 1005; DG-031) is an orally active and selective 5-lipoxygenase activating protein (FLAP) inhibitor[1]. Veliflapon inhibits the synthesis of the leukotrienes B4 and C4[2].
Product Specifications
CAS Number
128253-31-6
Product Name Alternative
BAY X 1005; DG-031
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
FLAP; Leukotriene Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/veliflapon.html
Purity
99.31
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(O)[C@H](C1CCCC1)C(C=C2)=CC=C2OCC3=NC4=CC=CC=C4C=C3
Molecular Formula
C23H23NO3
Molecular Weight
361.43
Precautions
H302, H315, H319, H335
References & Citations
[1]Müller-Peddinghaus R, et al. BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. J Pharmacol Exp Ther. 1993 Oct;267 (1) :51-7.|[2]Fruchtmann R, et al. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Agents Actions. 1993 Mar;38 (3-4) :188-95.|[3]Jawień J, et al. BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58 (3) :583-8.|[4]Hatzelmann A, et al. Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: implications for biological regulation of 5-lipoxygenase. Agents Actions. 1994 Nov;43 (1-2) :64-8.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
LTB4; LTC4/CysLT2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
